Elevance Health, Inc.

Listed Company

ELVCIK 0001156039NYSELarge AcceleratedHospital & Medical Service PlansIndianaFY ends Dec 31

Period

FY 2025

Revenue

$199.13B

Net Income

$5.66B

Total Assets

$121.49B

Equity

$43.88B

Shares Out

217.16M

Op. Cash Flow

$4.29B

Business

Elevance Health, Inc. is a leading health company that serves people across their entire health journey with an integrated whole‑health approach focused on improving health outcomes and managing care costs. It offers managed care risk‑based plans (Individual, Employer Group, Medicare, Medicaid, FEP®), pharmacy services, care delivery and analytics, and a broad array of administrative and specialty services (claims processing, stop loss, dental, vision, wellness and care management). The company reports results in four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. It operates nationally, licensed in all 50 states, the District of Columbia and Puerto Rico, and distributes products through direct sales, independent agents and brokers, public exchanges, employer channels and federal/state program contracts.

Summary from filing dated 2025-02-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Premiums	164,639	144,166	142,854	133,229	117,373
Total operating revenue	197,584	175,204	170,209	155,660	136,943
Net investment income	2,194	2,051	1,825	1,485	1,378
Net losses on financial instruments	−653	−445	−694	−550	318
Gain on sale of business	0	201	0	0	—
Total revenues	199,125	177,011	171,340	156,595	138,639
Benefit expense	148,223	127,567	124,330	116,642	102,571
Cost of products sold	21,178	19,750	17,293	13,035	10,895
Operating expense	20,984	20,025	20,087	17,700	15,918
Interest expense	1,402	1,185	1,030	851	—
Amortization of other intangible assets	628	580	885	767	441
Total expenses	192,415	169,107	163,625	148,995	130,644
Income before income tax expense	6,710	7,904	7,715	7,600	7,995
Income tax expense	1,049	1,933	1,724	1,712	1,846
Net income	5,661	5,971	5,991	5,888	6,149
Net loss (gain) attributable to noncontrolling interests	1	9	−4	6	9
Shareholders net income	5,662	5,980	5,987	5,894	6,158
Basic (in dollars per share)	25.28	25.81	25.38	24.56	25.26
Diluted (in dollars per share)	25.21	25.68	25.22	24.28	24.95

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	9,491	8,288	6,526	7,387	4,880
Fixed maturity securities (amortized cost of $25,773 and $25,879; allowance for credit losses of $21 and $6)	25,884	25,201	29,614	25,952	26,267
Equity securities	740	1,192	229	953	1,881
Premium receivables	10,073	8,011	7,902	7,083	5,681
Self-funded receivables	5,162	5,044	4,558	4,663	4,010
Other receivables	6,307	6,016	5,405	4,298	3,749
Other current assets	5,344	4,700	5,795	5,281	4,654
Assets held for sale	0	490	0	—	—
Total current assets	63,001	58,942	60,029	55,617	51,122
Fixed maturity securities (amortized cost of $1,116 and $1,049; allowance for credit losses of $0 and $0)	1,121	1,035	876	752	632
Other invested assets	10,839	9,749	6,107	5,685	5,225
Property and equipment, net	4,679	4,652	4,359	4,316	3,919
Goodwill	28,344	28,277	25,317	24,383	24,228
Other intangible assets	11,200	12,094	10,273	10,315	10,615
Other noncurrent assets	2,310	2,140	1,967	1,687	1,719
Total assets	121,494	116,889	108,928	102,755	97,460
Medical claims payable	17,084	15,746	16,111	15,596	13,518
Other policyholder liabilities	3,632	4,204	5,600	5,933	5,521
Unearned income	1,493	1,508	1,402	1,112	1,153
Accounts payable and accrued expenses	7,322	6,927	6,910	5,607	4,970
Short-term borrowings	150	365	225	265	275
Current portion of long-term debt	1,099	1,649	1,649	1,500	1,599
Other current liabilities	10,255	10,029	9,894	9,683	7,849
Liabilities held for sale	0	153	0	—	—
Total current liabilities	41,035	40,581	41,791	39,696	34,885
Long-term debt, less current portion	30,797	29,218	23,246	22,349	21,157
Reserves for future policy benefits	145	190	778	803	802
Deferred tax liabilities, net	2,110	2,148	1,970	2,015	2,805
Other noncurrent liabilities	3,381	3,326	1,738	1,562	1,683
Total liabilities	77,468	75,463	69,523	66,425	61,332
Commitments and ContingenciesNote 14	—	—	—	—	—
Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none	0	0	0	0	0
Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 220,723,898 and 227,479,695	2	2	2	2	2
Additional paid-in capital	8,938	8,911	8,868	9,084	9,148
Retained earnings	35,393	33,549	31,749	29,647	27,088
Accumulated other comprehensive loss	−451	−1,147	−1,313	−2,490	−197
Total shareholders equity	43,882	41,315	39,306	36,243	36,060
Noncontrolling interests	144	111	99	87	68
Total equity	44,026	41,426	39,405	36,330	36,140
Total liabilities and equity	121,494	116,889	108,928	102,755	97,460

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Equity in net (earnings) losses of other invested assets	−398	−1	33	−293	−562
Depreciation and amortization	1,546	1,393	1,745	1,675	1,302
Deferred income taxes	−279	−374	−602	−115	342
Impairment of property, equipment and right-of-use assets	108	103	446	7	73
Share-based compensation	276	191	289	264	255
Receivables, net	−2,526	−683	−1,762	−2,510	−2,138
Other invested assets	0	−78	−79	11	−70
Other assets	57	824	−675	133	41
Policy liabilities	228	−1,840	147	2,411	2,523
Unearned income	−15	−113	290	−42	−113
Accounts payable and other liabilities	−720	−272	1,640	824	719
Income taxes	−297	404	−103	−338	140
Other, net	−4	39	7	−66	21
Net cash provided by operating activities	4,290	5,808	8,061	8,399	8,364
Purchases of investments	−15,026	−17,986	−16,236	−24,946	−18,669
Proceeds from sale of investments	13,324	16,547	10,596	11,988	10,269
Maturities, calls and redemptions from investments	1,771	2,025	2,940	10,620	4,344
Changes in securities lending collateral	−385	73	78	−301	−956
Purchases of subsidiaries, net of cash acquired	88	−4,809	−1,552	−649	−3,476
Proceeds from sales of subsidiaries, net of cash sold	0	363	0	0	—
Purchases of property and equipment	−1,116	−1,256	−1,296	−1,152	−1,087
Other, net	0	−124	−102	−120	−63
Net cash used in investing activities	−1,344	−5,167	−5,572	−4,560	−9,638
Proceeds from long-term borrowings, net issuance costs	2,991	7,710	2,574	3,071	3,462
Repayments of long-term borrowings	−2,147	−1,650	−1,909	−1,899	−1,068
Proceeds from short-term borrowings	1,505	275	225	1,365	1,375
Repayments of short-term borrowings	−1,720	−135	−265	−1,675	−1,050
Changes in securities lending payable	386	−75	−77	302	956
Changes in bank overdrafts	1,312	−638	114	933	−376
Repurchase and retirement of common stock	−2,605	−2,900	−2,676	−2,316	−1,900
Cash dividends	−1,529	−1,508	−1,395	−1,229	−1,104
Proceeds from issuance of common stock under employee stock plans	79	221	152	182	—
Taxes paid through withholding of common stock under employee stock plans	−32	−109	−99	−93	−102
Other, net	22	2	7	41	27
Net cash provided by (used in) financing activities	−1,738	1,193	−3,349	−1,318	423
Effect of foreign exchange rates on cash and cash equivalents	−5	−6	−1	−14	−10
Change in cash and cash equivalents	1,203	1,828	−861	2,507	−861

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro